Anti-Human IL-6R (Sarilumab) – Biotin
Anti-Human IL-6R (Sarilumab) – Biotin
Product No.: LT1701
Product No.LT1701 Clone Hu137 Target IL-6 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 Isotype Human IgG1κ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893926 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B N IHC (Paraffin) IHC (Frozen) WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. Background IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects. Antigen Distribution IL-6R is ubiquitously expressed. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cell Biology . Immunology . Innate Immunity . Neuroscience . Other Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Sarilumab biosimilars are used as calibration standards or reference controls in PK bridging ELISAs by preparing standard curves that enable the quantification of Sarilumab concentrations in human serum samples, ensuring cross-comparability between biosimilar and reference products within a single validated assay. To measure drug concentrations using a bridging ELISA in PK studies:
This approach—using research-grade biosimilar as the calibration (analytical) standard—meets regulatory and scientific requirements for a robust and bridging-capable bioanalytical method in biosimilar PK studies. Essential points:
Typical ELISA procedure steps (using a research-grade Sarilumab biosimilar standard):
This standardized practice ensures accurate, directly comparable PK data for biosimilar and reference Sarilumab, which is critical for regulatory bridging and bioequivalence studies. Flow Cytometry Protocols for Sarilumab Biosimilar ConjugatesFlow cytometry (FACS) is a common technique to validate the expression and binding capacity of interleukin-6 receptor (IL-6R) using conjugated antibodies such as PE (phycoerythrin) or APC (allophycocyanin) labeled sarilumab biosimilars. These protocols generally follow standard immunophenotyping procedures, adapted for the specific target and antibody used. Major Steps in the Protocol
Experimental Controls and Optimization
Example Protocol Outline
Key Considerations
Summary Table: Key Parameters
These protocols are adaptable and should be optimized for the specific cell type, instrument, and research question, but the above provides a robust framework for validating IL-6R expression and binding using a conjugated sarilumab biosimilar in flow cytometry. Biopharma companies perform a range of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator (reference) biologic. These assays examine both molecular structure and biological function, and are fundamental in demonstrating “no clinically meaningful differences” between biosimilar and reference products. Key Analytical Assays Used:
Assay Strategy and Regulatory Emphasis:
Role of Leinco Biosimilars in Analytical Comparability Studies:Leinco Technologies supplies off-the-shelf biosimilar reference antibodies and proteins that are widely used as reference standards or comparators in these analytical and functional similarity assessments. In this context:
No detailed assay protocols involving Leinco biosimilars are described in the provided search results; however, their routine use is as comparators or controls to ensure accuracy, reproducibility, and regulatory compliance in analytical and functional similarity demonstrations—especially important in early development, assay qualification, and bridging studies. Summary of Typical Analytical Workflow:
If you require detailed examples of Leinco’s products or their use in specific assays, additional sources or company technical documentation may be needed, as the search results above provide only general context and do not detail Leinco-specific protocols. References & Citations1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1700 | |
LT1703 | |
LT1704 | |
LT1702 | |
LT1701 | |
LT1711 | |
LT1706 | |
LT1705 | |
LT1707 |
